Today: 8 February 2026
Subscribe
Browse Category

Pharmaceuticals News 4 February 2026 - 6 February 2026

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk shares rose nearly 5% Friday after the FDA said it would target mass-marketed, unapproved drug copies. The move follows Hims & Hers launching a $49 compounded version of Novo’s Wegovy pill, prompting Novo to threaten legal action. The stock remains near its 52-week low after a sharp drop earlier this week. Investors await FDA enforcement and Novo’s next legal steps.
6 February 2026
··
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie shares rose 0.7% to $219.02 in after-hours trading Thursday, rebounding after a nearly 6% drop following its earnings report. Skyrizi beat sales estimates with $5.01 billion, while Rinvoq missed at $2.37 billion. The company raised its 2026 forecast for the pair to $31.6 billion. Investors remain focused on whether new drugs can offset Humira’s ongoing decline.
6 February 2026
···
Eli Lilly stock price sinks after $49 weight-loss pill jolt hits LLY

Eli Lilly stock price sinks after $49 weight-loss pill jolt hits LLY

Eli Lilly shares fell 7.8% to $1,020.84 in after-hours trading Thursday after Reuters reported Hims & Hers began selling a $49 compounded version of Novo Nordisk’s Wegovy, raising discount fears in the GLP-1 drug market. Earlier, Lilly posted a 43% jump in quarterly revenue to $19.29 billion, led by Mounjaro and Zepbound, and forecast 2026 sales above Wall Street estimates.
5 February 2026
··
Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval

Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval

Merck shares rose about 2% to $120.72 Thursday after forecasting 2026 sales and profits below Wall Street estimates, citing patent expiries on older drugs. The company reported Q4 global sales of $16.4 billion and non-GAAP EPS of $2.04, and expects 2026 sales of $65.5–$67.0 billion. Health Canada approved ENFLONSIA for RSV prevention in infants. FDA review of WINREVAIR is set for September 21, 2026.
5 February 2026
··
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Johnson & Johnson shares rose 1.3% to $237.59 after the company asked the U.S. Supreme Court to review a shareholder lawsuit over talc safety claims. The petition challenges a Third Circuit ruling on class certification standards. The case is separate from ongoing talc injury suits. Investors are also watching for new data on J&J’s atrial fibrillation devices at a cardiology event this week.
5 February 2026
··
Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb shares rose 1.7% to $58.58 by midday Thursday, bucking a broader market decline, after the company issued a 2026 outlook projecting up to $47.5 billion in revenue. Quarterly revenue increased 1% to $12.5 billion, with growth portfolio sales up 16% and legacy drugs down 15%. The company expects Eliquis sales to rise despite U.S. price negotiations, but warned of a potential $2 billion drop in 2027 when European patents expire.
5 February 2026
··
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 February 2026
···
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
···
Eli Lilly stock slides after $49 Wegovy copy stirs fresh price-war jitters in obesity drugs

Eli Lilly stock slides after $49 Wegovy copy stirs fresh price-war jitters in obesity drugs

Eli Lilly shares fell 6.2% to $1,038.52 Thursday morning after Hims & Hers Health announced a $49-per-month compounded Wegovy pill, undercutting branded obesity drugs. Novo Nordisk shares also dropped 6.8%. Investors focused on Lilly’s ability to protect margins as cheaper alternatives and new pricing models intensify competition. CFO Lucas Montarce warned price cuts will slow growth despite strong demand.
5 February 2026
··
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer shares rose 3.9% to $26.78 before holding steady after hours, following new data on its obesity drug PF-3944 and quarterly results. The company maintained its 2026 revenue and earnings outlook but warned of pricing pressures and upcoming patent expirations. Mid-stage trial data showed up to 12.3% weight loss at 28 weeks, with some patients dropping out due to side effects. Trading volume topped 80 million shares.
5 February 2026
·
Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck shares rose 2.2% to $118.33 in after-hours trading Wednesday after new data showed its experimental cholesterol drug enlicitide cut LDL by up to 60% in a major trial. The company’s 2026 revenue forecast of $65.5–$67.0 billion missed Wall Street estimates, citing pressure from off-patent drugs and U.S. pricing. Keytruda sales reached $8.37 billion last quarter, while Gardasil revenue fell 34%.
5 February 2026
···
AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie stock slides after earnings: Rinvoq miss dents ABBV despite upbeat 2026 view

AbbVie shares fell 3.9% in after-hours trading Wednesday after quarterly results showed Rinvoq sales missed expectations at $2.37 billion. Skyrizi sales beat forecasts at $5.01 billion, while Humira revenue dropped 25.9% to $1.25 billion. The company projected 2026 adjusted earnings above estimates, but investors focused on challenges replacing Humira as biosimilar competition grows.
5 February 2026
···
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates

AbbVie shares fell 2.5% to $219.98 Wednesday after Rinvoq sales missed forecasts, despite the company raising its 2026 profit outlook. Q4 adjusted earnings reached $2.71 per share on $16.618 billion revenue; Skyrizi sales rose 32.5%, while Humira dropped 25.9%. AbbVie announced a three-year Medicaid pact with the Trump administration and pledged $100 billion in U.S. investments.
4 February 2026
···
Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson shares rose 1% to $235.50 Wednesday, bucking a broader market decline. RBC raised its price target to $255, citing strong financials despite ongoing talc litigation. New data showed ERLEADA cut prostate cancer death risk by 51% versus darolutamide. Investors await updates at the AF Symposium on Feb. 6 and a TD Cowen event on March 3.
4 February 2026
···
Merck stock price rises today as MRK rallies on Keytruda strength despite soft 2026 outlook

Merck stock price rises today as MRK rallies on Keytruda strength despite soft 2026 outlook

Merck shares rose 2.8% to $119.11 by midday Wednesday after the company beat Q4 expectations, but projected 2026 revenue of $65.5–$67.0 billion, below analyst forecasts. Keytruda sales climbed 7% while Gardasil dropped 34% on weak China demand. The company cited a $2.5 billion hit from generic drugs and U.S. pricing pressure. Investors remain focused on Merck’s ability to offset declines in older products.
4 February 2026
··
Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk stock plunges as 2026 sales warning fuels price-war fears around Wegovy

Novo Nordisk shares fell 16% in Copenhagen after the company warned 2026 sales and profit may drop up to 13% due to falling U.S. drug prices and tougher competition. ADRs slid nearly 4% in New York. Novo plans a share buyback of up to 15 billion Danish crowns and named Jamey Millar as its new U.S. head. CEO Mike Doustdar said Wegovy price cuts have hit results but are meant to boost future demand.
4 February 2026
···
1 2 3 4 … 34

Stock Market Today

Hua Hong Semiconductor Class A stock price: two dates traders can’t ignore after Friday’s drop

Hua Hong Semiconductor Class A stock price: two dates traders can’t ignore after Friday’s drop

8 February 2026
Hua Hong Semiconductor’s Shanghai-listed shares fell 0.6% to 130.26 yuan Friday, down 16% for the week. Shareholders will vote Feb. 10 on an acquisition and share issuance plan, with a board meeting set for Feb. 12 to review unaudited quarterly results. The company aims to buy nearly all of Shanghai Huali Microelectronics for 8.27 billion yuan, funded by new shares and a private placement.
First Solar stock price slides into next week as Tesla ramps solar hiring; earnings due Feb. 24

First Solar stock price slides into next week as Tesla ramps solar hiring; earnings due Feb. 24

8 February 2026
First Solar shares fell 6.7% to $218.73 Friday, trading over double their 50-day average volume as the broader market rallied. Tesla announced hiring tied to Elon Musk’s 100-gigawatt U.S. solar manufacturing goal. First Solar will report Q4 and full-year 2025 results and 2026 guidance on Feb. 24. Policy changes and competitive moves have heightened volatility in the U.S. solar sector.
GlobalFoundries stock jumps nearly 5% ahead of earnings — what could move GFS next week

GlobalFoundries stock jumps nearly 5% ahead of earnings — what could move GFS next week

8 February 2026
GlobalFoundries shares rose 4.7% to $42.91 Friday as chip stocks rebounded, tracking a surge in the PHLX semiconductor index and renewed bets on AI-driven demand. The company reports earnings Feb. 11, with analysts watching for updates on pricing and wafer shipment volumes. The Semiconductor Industry Association forecast global chip sales could hit $1 trillion in 2026.
Go toTop